Intrathecal CGX-1007 is neuroprotective in a rat model of focal cerebral ischemia.

Abstract

The NMDA antagonist CGX-1007 (Conantokin-G) has previously been shown to possess potent neuroprotective properties when administered intracranially following experimental ischemic brain injury. Using the same model of middle cerebral artery occlusion (MCAo) in rats we now report the neuroprotective effects of CGX-1007 when delivered intrathecally (i.t.). When given 4 h post-occlusion, a reduction in brain infarction was measured along with significant neurological recovery. Furthermore, we describe an i.t. neuroprotective therapeutic window lasting > or = 8 h from the start of the injury. Critically, this is the first comprehensive report of a neuroprotective agent that can be administered i.t. to ameliorate experimental brain injury and potentially provide an excellent therapeutic window as a neuroprotection treatment.

• Authors: Anthony J Williams, Geoff Ling, R Tyler McCabe, Frank C Tortella
• Journal: Neuroreport (Neuroreport) Vol. 13 Issue 6 Pg. 821-4 (May 07 2002) ISSN: 0959-4965 [Print] England
• PMID: 11997694 (Publication Type: Journal Article)

Chemical References

• Conotoxins
• Excitatory Amino Acid Antagonists
• Neuroprotective Agents
• conotoxin GV

Topics

• Animals
• Body Weight (drug effects, physiology)
• Brain Edema (drug therapy, etiology, physiopathology)
• Brain Ischemia (drug therapy, pathology, physiopathology)
• Cerebral Cortex (drug effects, pathology, physiopathology)
• Conotoxins (pharmacology)
• Corpus Striatum (drug effects, pathology, physiopathology)
• Disease Models, Animal
• Excitatory Amino Acid Antagonists (pharmacology)
• Fever (drug therapy, etiology, physiopathology)
• Infarction, Middle Cerebral Artery (drug therapy, pathology, physiopathology)
• Injections, Spinal
• Male
• Neuroprotective Agents (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Telencephalon (drug effects, pathology, physiopathology)
• Treatment Outcome